Compare Stocks: CTMX, LKFT, IMNM, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.00 -0.5%	$33.41	$22.24 ▼ $46.00	$2.21B	0.63	1.21 million shs	920,048 shs
CTMX CytomX Therapeutics	$2.32 -4.9%	$2.94	$2.20 ▼ $8.21	$505.53M	2.21	3.14 million shs	4.37 million shs
IMNM Immunome	$17.99 -1.5%	$23.39	$14.64 ▼ $30.06	$2.04B	2.55	1.46 million shs	1.38 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$31.65 +0.8%	$29.12	$25.68 ▼ $36.24	$2.09B	0.24	270,223 shs	294,936 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+18.14%	+12.46%	+1.76%	-11.36%
CTMX CytomX Therapeutics	0.00%	+1.75%	-15.64%	-28.40%	-31.56%
IMNM Immunome	0.00%	+9.23%	-19.47%	-19.00%	+13.14%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+5.85%	+4.25%	+13.69%	-0.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.00 -0.5%	$33.41	$22.24 ▼ $46.00	$2.21B	0.63	1.21 million shs	920,048 shs
CTMX CytomX Therapeutics	$2.32 -4.9%	$2.94	$2.20 ▼ $8.21	$505.53M	2.21	3.14 million shs	4.37 million shs
IMNM Immunome	$17.99 -1.5%	$23.39	$14.64 ▼ $30.06	$2.04B	2.55	1.46 million shs	1.38 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$31.65 +0.8%	$29.12	$25.68 ▼ $36.24	$2.09B	0.24	270,223 shs	294,936 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+18.14%	+12.46%	+1.76%	-11.36%
CTMX CytomX Therapeutics	0.00%	+1.75%	-15.64%	-28.40%	-31.56%
IMNM Immunome	0.00%	+9.23%	-19.47%	-19.00%	+13.14%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+5.85%	+4.25%	+13.69%	-0.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.50	12.16% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	412.93% Upside
IMNM Immunome	2.80	Moderate Buy	$34.25	90.38% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.38	Hold	$35.50	12.16% Upside

Current Analyst Ratings Breakdown

Latest CTMX, LKFT, IMNM, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Equal Weight	$26.00
10/16/2026	IMNM Immunome	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	IMNM Immunome	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	CTMX CytomX Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$39.00 ➝ $37.00
10/2/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
9/30/2026	IMNM Immunome	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold	$24.00
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $45.00
9/21/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
9/21/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$46.00 ➝ $50.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$98.34M	22.46	N/A	N/A	$20.46 per share	1.81
CTMX CytomX Therapeutics	$76.20M	6.63	N/A	N/A	$0.58 per share	4.00
IMNM Immunome	$6.94M	294.42	N/A	N/A	$5.75 per share	3.13
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.66	$0.73 per share	43.59	$47.57 per share	0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	11/5/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CTMX, LKFT, IMNM, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AGIO Agios Pharmaceuticals	-$1.25	N/A	N/A	N/A	$51.55 million	N/A
11/5/2026	Q3 2026	CTMX CytomX Therapeutics	-$0.09	N/A	N/A	N/A	$10.38 million	N/A
11/5/2026	Q3 2026	IMNM Immunome	-$0.6066	N/A	N/A	N/A	$0.15 million	N/A
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.03	+$0.9972	$0.0330	$7.29 million	$15.47 million
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
CTMX CytomX Therapeutics	N/A	9.36	9.36
IMNM Immunome	N/A	15.08	15.08
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CTMX CytomX Therapeutics	67.77%
IMNM Immunome	44.58%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
CTMX CytomX Therapeutics	3.80%
IMNM Immunome	7.21%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable

CTMX, LKFT, IMNM, and AGIO Headlines

Recent News About These Companies

Lakefront Biotherapeutics American Depositary Shares (LKFT) - What Are Analysts Thinking About This Stock?

3 hours ago | americanbankingnews.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Hold" by Wall Street Brokerages

3 hours ago | marketbeat.com

Morgan Stanley Begins Coverage on Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

October 22 at 2:03 AM | americanbankingnews.com

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?

October 21, 2026 | zacks.com

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year Fall

October 21, 2026 | finance.yahoo.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Rated "Equal Weight" in New Coverage at Morgan Stanley

October 20, 2026 | marketbeat.com

Lakefront (NASDAQ: LKFT) completes CAR-T program sale for up to $230 million

October 18, 2026 | americanbankingnews.com

Lakefront Biotherapeutics Nv Announces Sale of Preclinical Car-T Programs to Armed Cell Therapeutics Bv

October 16, 2026 | marketscreener.comM

Lakefront sells cell therapy pipeline for €8M upfront plus milestones

October 16, 2026 | streetinsider.com

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

October 14, 2026 | globenewswire.com

Acquisition of Own Shares

October 13, 2026 | globenewswire.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Strong Trading Volume - Should You Buy?

October 8, 2026 | marketbeat.com

Acquisition of Own Shares

October 6, 2026 | globenewswire.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

September 30, 2026 | marketbeat.com

Acquisition of Own Shares

September 29, 2026 | globenewswire.com

Lakefront Biotherapeutics Stock Rises 4% After Share Repurchase Update

September 24, 2026 | rttnews.com

Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says

September 23, 2026 | marketscreener.comM

RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26

September 23, 2026 | marketscreener.comM

Acquisition of Own Shares

September 22, 2026 | globenewswire.com

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 17, 2026 | seekingalpha.com

Acquisition of Own Shares

September 15, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, LKFT, IMNM, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$37.00 -0.19 (-0.51%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$37.00 0.00 (0.00%)

As of 10/23/2026 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CytomX Therapeutics NASDAQ:CTMX

$2.32 -0.12 (-4.92%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.35 +0.03 (+1.29%)

As of 10/23/2026 07:57 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$17.99 -0.27 (-1.48%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$18.00 +0.01 (+0.06%)

As of 10/23/2026 07:30 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$31.65 +0.25 (+0.80%)

As of 10/23/2026 04:00 PM Eastern

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, LKFT, IMNM, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, LKFT, IMNM, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, LKFT, IMNM, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, LKFT, IMNM, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

CytomX Therapeutics NASDAQ:CTMX

Immunome NASDAQ:IMNM

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, LKFT, IMNM, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, LKFT, IMNM, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, LKFT, IMNM, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, LKFT, IMNM, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

CytomX Therapeutics NASDAQ:CTMX

Immunome NASDAQ:IMNM

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools